Biontech plans to buy competitor Curevac for $ 1.25 billion to enhance MRNA -based cancer treatments.
Professor Dr. Uğur şahin and his wife are professors.dr. The creation of özlem Türeci, Biontech Biotechnology Company, has acted to buy competitor Curevac based on Tübingen.
Biontech claimed that Curevac sets a goal to take all his stocks and make a proposal in this direction.
In a statement made by the company, “with the completion of buying in the field of cancer treatment in the field of knowledge based on MRNA to strengthen.”
According to Türkiye DW, the scale of the sales process is expected to be about US $ 1.25 billion (about 1.08 billion euros). The parties hope the process will be completed by the end of 2025.